Skip to main content

Compare Stocks

Date Range: 

 Frequency TherapeuticsRedHill BiopharmaHookipa PharmaOrphazyme A/SAmpio Pharmaceuticals
SymbolNASDAQ:FREQNASDAQ:RDHLNASDAQ:HOOKNASDAQ:ORPHNYSEAMERICAN:AMPE
Price Information
Current Price$8.66$6.22$17.56$5.51$1.77
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.51.41.01.01.3
Analysis Score3.53.52.53.03.5
Community Score2.72.92.62.12.5
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.00.00.0
Earnings & Valuation Score0.60.60.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$37.00$20.00$21.86$16.00$4.00
% Upside from Price Target327.25% upside221.54% upside24.47% upside190.38% upside125.99% upside
Trade Information
Market Cap$296.34 million$288.58 million$456.47 million$192.59 million$346.37 million
Beta0.691.711.18N/A1.79
Average Volume1,130,866476,988183,60241,8073,047,174
Sales & Book Value
Annual Revenue$28.95 million$6.29 million$11.94 millionN/AN/A
Price / Sales10.2445.8838.23N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.44 per share$2.74 per share$5.46 per shareN/A$0.04 per share
Price / Book1.592.273.22N/AN/A
Profitability
Net Income$-18,750,000.00$-42,300,000.00$-43,040,000.00N/A$-13,630,000.00
EPS($2.29)($1.40)($2.41)N/A($0.14)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-68.59%-142.81%-232.00%N/AN/A
Return on Equity (ROE)-12.56%-152.19%-39.58%N/A-192.88%
Return on Assets (ROA)-9.92%-45.96%-31.33%N/A-97.89%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A2.79%0.05%N/AN/A
Current Ratio6.91%1.80%5.65%N/A5.65%
Quick Ratio6.91%1.64%5.65%N/A5.65%
Ownership Information
Institutional Ownership Percentage57.48%20.36%33.39%10.60%9.91%
Insider Ownership Percentage15.40%N/A4.02%N/A3.60%
Miscellaneous
Employees831825614118
Shares Outstanding34.22 million46.40 million26.00 million34.95 million195.69 million
Next Earnings Date8/11/2021 (Estimated)5/26/2021 (Estimated)8/12/2021 (Estimated)N/A7/30/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)
finance.yahoo.com - May 10 at 10:15 AM
EXCLUSIVE: Ampio Pharmaceuticals Approved For Clinical Study Of Lead Drug In Long-Term Respiratory COVID-19 SymptomsEXCLUSIVE: Ampio Pharmaceuticals Approved For Clinical Study Of Lead Drug In Long-Term Respiratory COVID-19 Symptoms
feeds.benzinga.com - May 10 at 9:18 AM
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Releases  Earnings Results, Hits EstimatesAmpio Pharmaceuticals (NYSEAMERICAN:AMPE) Releases Earnings Results, Hits Estimates
americanbankingnews.com - May 6 at 2:52 PM
Ampio: Q1 Earnings SnapshotAmpio: Q1 Earnings Snapshot
abqjournal.com - May 5 at 6:16 PM
Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business UpdateAmpio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 5 at 4:07 PM
Why should you add Ampio Pharmaceuticals Inc. (AMPE) to your portfolio?Why should you add Ampio Pharmaceuticals Inc. (AMPE) to your portfolio?
marketingsentinel.com - May 5 at 11:07 AM
Insider Selling: Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) Director Sells 20,000 Shares of StockInsider Selling: Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) Director Sells 20,000 Shares of Stock
americanbankingnews.com - April 30 at 6:10 PM
Holli Cherevka Sells 74,631 Shares of Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) StockHolli Cherevka Sells 74,631 Shares of Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) Stock
americanbankingnews.com - April 30 at 4:52 PM
Ampio Pharmaceuticals, Inc. (NYSE:AMPE) Stock Jumped 17.39% Over A Month – Is There Any Hope Of Further Gain?Ampio Pharmaceuticals, Inc. (NYSE:AMPE) Stock Jumped 17.39% Over A Month – Is There Any Hope Of Further Gain?
marketingsentinel.com - April 30 at 12:49 PM
Ampio Pharmaceuticals, Inc. (NYSE:AMPE)’s Upside Potential Is HighAmpio Pharmaceuticals, Inc. (NYSE:AMPE)’s Upside Potential Is High
stocksregister.com - April 29 at 1:24 PM
Ampio Pharmaceuticals Inc. [AMPE] moved up 3.21: Why It’s ImportantAmpio Pharmaceuticals Inc. [AMPE] moved up 3.21: Why It’s Important
dbtnews.com - April 29 at 12:04 AM
Ampio Pharmaceuticals (AMPE) Scheduled to Post Earnings on WednesdayAmpio Pharmaceuticals (AMPE) Scheduled to Post Earnings on Wednesday
americanbankingnews.com - April 28 at 6:30 AM
Ampio Pharmas Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause MortalityAmpio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality
finance.yahoo.com - April 27 at 1:55 PM
Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19
finance.yahoo.com - April 27 at 9:24 AM
Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%
finance.yahoo.com - April 27 at 9:24 AM
Ampio Pharmaceuticals, Inc. (NYSE:AMPE)up 3.21%: This is what analysts are now forecastingAmpio Pharmaceuticals, Inc. (NYSE:AMPE)up 3.21%: This is what analysts are now forecasting
stocksregister.com - April 22 at 9:07 AM
Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business UpdateAmpio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business Update
finance.yahoo.com - April 21 at 10:22 AM
Ampio Pharmaceuticals, Inc. (NYSE:AMPE) Stock Could Reward Investors With a 154.78% GainAmpio Pharmaceuticals, Inc. (NYSE:AMPE) Stock Could Reward Investors With a 154.78% Gain
marketingsentinel.com - April 20 at 12:34 PM
Ampio Pharmaceuticals, Inc. (NYSE:AMPE) Stock Forecast: Bullish Sentiment Portends 154.78% Upside in 2021Ampio Pharmaceuticals, Inc. (NYSE:AMPE) Stock Forecast: Bullish Sentiment Portends 154.78% Upside in 2021
stocksregister.com - April 19 at 10:18 AM
Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse EffectsResearch Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse Effects
finance.yahoo.com - April 19 at 10:02 AM
Is Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a Good Pick for New Investors Now?Is Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a Good Pick for New Investors Now?
stocksregister.com - April 12 at 6:59 PM
Ampio posts encouraging results from Ampion COVID-19 pre-clinical studyAmpio posts encouraging results from Ampion COVID-19 pre-clinical study
seekingalpha.com - April 8 at 1:57 PM
Ampio Pharmaceuticals Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus NephritisAmpio Pharmaceuticals' Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis
finance.yahoo.com - April 6 at 10:11 AM
Ampio Pharmaceuticals is Building on its Progress in Tackling Osteoarthritis and COVID-19 Respiratory IssuesAmpio Pharmaceuticals is Building on its Progress in Tackling Osteoarthritis and COVID-19 Respiratory Issues
markets.businessinsider.com - April 1 at 12:29 PM
Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International CongressAmpio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress
finance.yahoo.com - March 29 at 9:32 AM
DateCompanyBrokerageAction
3/30/2021Frequency TherapeuticsOppenheimerLower Price Target
3/24/2021Frequency TherapeuticsB. RileyLower Price Target
1/27/2021Frequency TherapeuticsJPMorgan Chase & Co.Upgrade
11/18/2019Frequency TherapeuticsCowenReiterated Rating
10/28/2019Frequency TherapeuticsThe Goldman Sachs GroupInitiated Coverage
11/12/2020RedHill BiopharmaRoth CapitalLower Price Target
10/13/2020RedHill BiopharmaAscendiant Capital MarketsReiterated Rating
9/11/2020RedHill BiopharmaBTIG ResearchInitiated Coverage
3/5/2020RedHill BiopharmaHC WainwrightReiterated Rating
7/12/2019RedHill BiopharmaWBB SecuritiesUpgrade
12/12/2018RedHill BiopharmaLADENBURG THALM/SH SHSet Price Target
4/14/2021Hookipa PharmaMorgan StanleyInitiated Coverage
3/21/2021Hookipa PharmaSVB LeerinkReiterated Rating
11/30/2020Hookipa PharmaJMP SecuritiesBoost Price Target
11/3/2020Hookipa PharmaTruist FinancialInitiated Coverage
8/16/2020Hookipa PharmaRoyal Bank of CanadaReiterated Rating
5/13/2019Hookipa PharmaBank of AmericaInitiated Coverage
10/26/2020Orphazyme A/SGuggenheimInitiated Coverage
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.